Место блокаторов рецепторов ангиотензина в антигипертензивной терапии
Аннотация
Об авторах
Анатолий Иванович МартыновРоссия
Инна Владимировна Урлаева
Россия
Евгения Владимировна Акатова
Россия
Олеся Петровна Николин
Россия
Список литературы
1. Диагностика и лечение артериальной гипертензии. Кардиоваск. терапия и профилактика. 2008; 7 (6). Прил. 2.
2. ESH-ESC Guidelines Committee. 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.
3. Neutel J et al. Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild - to - Moderate Hypertension.J RAAS 2005; 6: 84-9.
4. Mimran A et al. A rindomised, double - blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild - to - moderate hypertension. J Hum Hypertens 1998; 12: 203-8.
5. Stumpe K.O et al. Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension Blood Press 1998; 7: 31-7.
6. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efcacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-42.
7. Kassler-Taub K et al. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild - to - Moderate Hypertension. Am J Hypertens 1998; 11: 445-53.
8. Fogari R et al. 24-Hour blood pressure control by once - daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511-8.
9. Neutel J.M et al. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. J Hypertens 2006; 24: S284.
10. Parving H.H, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
11. Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
12. Madrid A.H, Marнn I.M, Cervantes C.E et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose - dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 114-20.
13. Larochelle P et al. for the Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613-5.
14. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
15. Neutel J.M, Saunders E, Bakris G.L et al. INCLUSIVE Investigators. The efficacy and safety of low - and high - dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7 (10): 578-86.
16. Kohar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild - to - moderate hypertension. Am J Hypertens 1999; 12: 797-805.
17. Hasford J et al. A population - based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569-75.
Рецензия
Для цитирования:
Мартынов А.И., Урлаева И.В., Акатова Е.В., Николин О.П. Место блокаторов рецепторов ангиотензина в антигипертензивной терапии. Системные гипертензии. 2014;11(1):34-39.
For citation:
Martynov A.I., Urlaeva I.V., Akatova E.V., Nikolin O.P. Place of angiotensin receptor blockers in antihypertensive therapy. Systemic Hypertension. 2014;11(1):34-39.
Послать статью по эл. почте 